Modulation

HyperLight Expands Electro-Optical Modulator Product Line to 110GHz, 65GHz, and 20GHz with Sub-Volt Half-Wave Voltage

Retrieved on: 
Wednesday, March 20, 2024
Technology, Mobile, Wireless, Semiconductor, Engineering, Telecommunications, Nanotechnology, Manufacturing, Internet, Hardware, Conference, EOM, Thorlabs, MX110, TFLN, Modulation, Hertz, Programmable interrupt controller, PIC, Multimedia, Mobile phone

HyperLight, the leading provider of integrated electro-optical modulators (EOMs), is proud to announce the expansion of its intensity modulator series.

Key Points: 
  • HyperLight, the leading provider of integrated electro-optical modulators (EOMs), is proud to announce the expansion of its intensity modulator series.
  • This announcement underscores HyperLight’s continued commitment to cutting edge innovation of photonics integrated circuits (PICs).
  • HyperLight is adding a new low half-wave-voltage (Vπ) 65 GHz Intensity Modulator to its modulator line-up.
  • Concurrently, HyperLight is unveiling the 20 GHz Ultra Low Vπ Intensity Modulator, achieving a groundbreaking Vπ of

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
Monday, March 11, 2024
SAN, Ulcerative colitis, Week, CDAI, IC50, Solipsism syndrome, Peripheral, Obesity, Cerebrospinal fluid, Cardiovascular disease, Treatment, MACE, NLRP3, Volunteering, Inflammation, Modulation, QD, Safety, Biomarker, UC, CAPS, Pharmacokinetics, Webcast, Patient, Molina Healthcare, TYK2, CSF, PIPE, Plasma, FCAS, Risk, Pharmaceutical industry

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Tuesday, February 27, 2024
SAN, Ulcerative colitis, Quarter, Week, CDAI, Peripheral, Blood, Obesity, ALS, Research and development, Cryopyrin-associated periodic syndrome, NLRP3, Volunteering, Inflammation, Modulation, Multiple sclerosis, Rheumatology, Safety, UC, CAPS, CNS, Administration, Pharmacokinetics, Patient, TYK2, FCAS, G&A, Ulcer, Pharmaceutical industry

SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and marketable securities were $252.2 million as of December 31, 2023.
  • Research and Development (R&D) expenses: R&D expenses were $42.0 million for the fourth quarter of 2023, compared to $30.2 million for the fourth quarter of 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.3 million for the fourth quarter of 2023, compared to $8.4 million for the fourth quarter of 2022.
  • Net loss: Net loss was $46.8 million for the fourth quarter of 2023, compared to $35.2 million for the fourth quarter of 2022.

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Retrieved on: 
Thursday, November 9, 2023
CNS, FCAS, Cryopyrin-associated periodic syndrome, Safety, SAN, ALS, Modulation, Psoriasis, Administration, Patient, Research and development, Inflammation, TYK2, Pharmacokinetics, Ulcerative colitis, Blood, Psoriatic arthritis, Multiple sclerosis, R, NLRP3, Phase II, Volunteering, UC, Peripheral, Cryptocurrency, Pharmaceutical industry, CAPS

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent pipeline and business progress.

Key Points: 
  • Accordingly, we have elected to terminate ongoing activities in the Phase 2 trials of VTX958 in plaque psoriasis and psoriatic arthritis.
  • Research and Development (R&D) expenses: R&D expenses were $49.8 million for the quarter ended September 30, 2023, compared to $25.5 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) expenses: G&A expenses were $8.2 million for the quarter ended September 30, 2023, compared to $6.0 million for the quarter ended September 30, 2023.
  • Net loss: Net loss was $54.0 million for the quarter ended September 30, 2023, compared to $30.5 million for the quarter ended September 30, 2022.

Intel and NewPhotonics Achieve Breakthrough with 224Gbps Electrical SerDes and Photonics Engine Integration

Retrieved on: 
Tuesday, December 5, 2023
Intel, PAM4, PD, Modulation, Digital signal processing, ECOC, DSP, Photonics, Digital signal, TEL, SerDes, Renewable energy

TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Intel Corporation and NewPhotonics Ltd are proud to announce a milestone achievement: the successful integration of Intel new 224Gbps electrical SerDes design with NewPhotonics cutting-edge Photonics Engine, resulting in an end-to-end direct modulation electrical-to-optical link utilizing PAM4 modulation.

Key Points: 
  • TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Intel Corporation and NewPhotonics Ltd are proud to announce a milestone achievement: the successful integration of Intel new 224Gbps electrical SerDes design with NewPhotonics cutting-edge Photonics Engine, resulting in an end-to-end direct modulation electrical-to-optical link utilizing PAM4 modulation.
  • Unprecedented Speed and Scalability: The integration of Intel SerDes design and the NewPhotonics Photonics Engine achieved a 224Gbps end-to-end data transmission rate with exceptional performance.
  • "We are thrilled to have achieved the successful integration of our photonics technology with Intel most advanced 224Gbps SerDes."
  • Noam Avni, Intel Vice President, added, "Our advanced SerDes designs, combined with NewPhotonics optical engine, demonstrates the power of pushing the boundaries of technology.

Intel and NewPhotonics Achieve Breakthrough with 224Gbps Electrical SerDes and Photonics Engine Integration

Retrieved on: 
Tuesday, December 5, 2023
Intel, PAM4, PD, Modulation, Digital signal processing, ECOC, DSP, Photonics, Digital signal, TEL, SerDes, Renewable energy

TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Intel Corporation and NewPhotonics Ltd are proud to announce a milestone achievement: the successful integration of Intel new 224Gbps electrical SerDes design with NewPhotonics cutting-edge Photonics Engine, resulting in an end-to-end direct modulation electrical-to-optical link utilizing PAM4 modulation.

Key Points: 
  • TEL AVIV, Israel, Dec. 5, 2023 /PRNewswire/ -- Intel Corporation and NewPhotonics Ltd are proud to announce a milestone achievement: the successful integration of Intel new 224Gbps electrical SerDes design with NewPhotonics cutting-edge Photonics Engine, resulting in an end-to-end direct modulation electrical-to-optical link utilizing PAM4 modulation.
  • Unprecedented Speed and Scalability: The integration of Intel SerDes design and the NewPhotonics Photonics Engine achieved a 224Gbps end-to-end data transmission rate with exceptional performance.
  • "We are thrilled to have achieved the successful integration of our photonics technology with Intel most advanced 224Gbps SerDes."
  • Noam Avni, Intel Vice President, added, "Our advanced SerDes designs, combined with NewPhotonics optical engine, demonstrates the power of pushing the boundaries of technology.

Lightwave Logic Issues Shareholder Letter and Provides Corporate Update

Retrieved on: 
Monday, December 4, 2023
Cloud, Sale, Invention, Photonic integrated circuit, SEM, Engineering, All Access Europe, PIC, 1310, End-user license agreement, Die (integrated circuit), Polymer, Learning, History, Modulation, Intellectual property, Artificial intelligence, Optica, LightWave 3D, Patent, License, Conference, Internet, Growth, Programmable interrupt controller, AI, Silicon, Letter, EO, Travel, Logic, Internet service provider, 3D printing, Television, Management

ENGLEWOOD, Colo., Dec. 4, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today issued a letter to shareholders from its Chairman and Chief Executive Officer, Dr. Michael Lebby.

Key Points: 
  • 2023 has been a transformational year for Lightwave Logic, underscored by the first commercial material supply and license agreement for our electro-optic polymer materials and ongoing efforts to build on this commercialization momentum.
  • Throughout the year we focused on industry awareness efforts, evangelizing the benefits of our platform at leading industry events globally.
  • Per the terms of the non-exclusive material supply and license agreement, the licensee shall pay Lightwave Logic a running royalty with a minimum royalty paid on an annual basis over the term of the License Agreement.
  • I will be hosting a fireside chat today with the hosts of the Benzinga All-Access show to discuss this shareholder letter, recent milestone achievements and potential near-term catalysts.

Lightwave Logic Provides Third Quarter 2023 Corporate Update

Retrieved on: 
Friday, November 10, 2023
Cloud, SEM, Acquisition, Engineering, Shareware Industry Awards, PIC, IP, Polymer, Learning, Innovation, Communes of Burundi, Modulation, LightWave 3D, ECOC, OEM, Conference, Partnership, Exhibition, Original equipment manufacturer, Programmable interrupt controller, AI, EO, Logic, Satellite navigation device, Video game

ENGLEWOOD, Colo., Nov. 10, 2023 /PRNewswire/ -- Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today provided a corporate update in conjunction with the filing of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023.

Key Points: 
  • As of September 30, 2023, the company had cash and cash equivalents of $30 million, enabling the company to finance operations through April 2025.
  • Received the 2023 Industry Award for Most Innovative Hybrid PIC/Optical Integration Platform from the European Conference on Optical Communications (ECOC) - a premier industry exhibition.
  • The full text of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 was filed with the SEC on November 9, 2023 and can be found here .
  • "We expanded our corporate facility in Englewood, Colorado by nearly 10,000 square feet for a total of approximately 23,500 square feet.

Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update

Retrieved on: 
Monday, November 6, 2023
Week, Modulation, Psoriasis, Phase II, UC, CAPS, Inflammation, BID, NLRP3, Volunteering, Ulcerative colitis, Psoriasis Area and Severity Index, Pharmacokinetics, Cryopyrin-associated periodic syndrome, FCAS, Webcast, Peripheral, SAN, Blood, Safety, Patient, PASI, Pharmaceutical industry

Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis.

Key Points: 
  • Although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support advancement of VTX958 in plaque psoriasis.
  • Accordingly, we will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately.
  • Based on these results, we have also elected to terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.
  • ET to discuss the results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis.

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Monday, October 16, 2023
Janus, Incidence, Language, NYSE, Food, UC, JAK, Proctitis, HKEX, Pfizer, Safety, First Affiliated Hospital of Xinjiang Medical University, Disease, Arena Pharmaceuticals, Ulcerative colitis, FDA, Mount Everest, Clinical trial, Modulation, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, PFE, Pharmaceutical industry

SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
  • Everest is conducting a multi-center Phase 3 clinical trial of etrasimod in Asia and aims to file New Drug Application as soon as possible.
  • "Etrasimod's FDA approval marks an important milestone for moderately to severely active UC patients who need new treatments for this chronic condition.
  • Everest Medicines obtained exclusive rights from Arena to develop, manufacture and commercialize etrasimod in Greater China and South Korea in 2017.